Alta Bioequities
2
83M
2
1
- Areas of investment
Summary
The top amount of exits for fund were in 2012. The important activity for fund was in 2015. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 3 participants. Despite the Alta Bioequities, startups are often financed by 5AM Ventures, GBS Ventures. The meaningful sponsors for the fund in investment in the same round are Stonepine Capital, 5AM Ventures. In the next rounds fund is usually obtained by Bridge Bank.
Among the most successful fund investment fields, there are Medical Device, Women's. Among the various public portfolio startups of the fund, we may underline Viveve Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Medical Device (1)
- Hardware (1)
- Women's (1)
- Health Care (1)
- Biopharma (1) Show 2 more
- Investments by region
-
- United States (2)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Group Appearance index
- 1.00
- Avg. company exit year
- 9
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.